Walleye Capital’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Walleye Capital’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,646,466	Closed	-$46.4K	–	6088
2024 Q2	$46.4K	Hold	1,646,466	–	–	﹤0.01%	4942
2024 Q1	$148K	Hold	1,646,466	–	–	﹤0.01%	4161
2023 Q4	$173K	Buy	1,646,466 +119,984	+8%	+$17.7K	﹤0.01%	3761
2023 Q3	$343K	Sell	1,526,482 -16,255	-1%	-$4.37K	﹤0.01%	3121
2023 Q2	$405K	Buy	1,542,737 +1,012,135	+191%	+$197K	﹤0.01%	2586
2023 Q1	$95.5K	Buy	530,602 +246,442	+87%	+$56.4K	﹤0.01%	2955
2022 Q4	$56.8K	Buy	+284,160	New	+$122K	﹤0.01%	2500
2022 Q1	–	Sell	-241,033	Closed	-$540K	–	2667
2021 Q4	$540K	Buy	241,033 +209,087	+655%	+$676K	0.02%	940
2021 Q3	$108K	Buy	+31,946	New	+$114K	﹤0.01%	1319

Other funds holding DNA.WS

Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Walleye Capital's DNA.WS Position: Q3 2024 in Review

Walleye Capital sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 1,646,466 shares — an estimated $46.4K sold.

Walleye Capital first reported a position in DNA.WS in Q3 2021 and held it in 9 quarters. The position peaked at $540K in Q4 2021. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

Walleye Capital reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 1,646,466 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024, an estimated $46.4K.
Walleye Capital first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 9 quarters.
Walleye Capital's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $540K in Q4 2021.
5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.